On Monday shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at $0.72. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on April 21, 2015, declared that it presented preclinical data on Supinoxin(TM) (RX-5902) at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. This presentation entitled, “Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)” was co-authored by Frances Fuller-Pace Ph.D., Division of Cancer Research, University of Dundee, United Kingdom and Rexahn scientists.
MannKind Corp. (NASDAQ:MNKD) in last trading activity moved up 4.55% to close at $4.37. Company weekly performance is -4.79% while its quarterly performance stands at -32.04%. MannKind Corp. (NASDAQ:MNKD) is -61.93% away from its 52 week high. MannKind Corporation (NASDAQ:MNKD) will release its 2015 first quarter financial results on Thursday, May 7, 2015 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 9:00 AM (Eastern Time) on May 8, 2015.
On last trading day Kaman Corporation (NYSE:KAMN) moved up 1.01% to close at $41.95. Its volatility for the week is 1.87% while volatility for the month is 1.56%. KAMN’s sales growth for past 5 years was 9.40% and its EPS growth for past 5 years was 19.60%. Kaman Corporation (NYSE:KAMN) monthly performance is -0.85%. Kaman Corp. (NYSE:KAMN) on 29 April, reported financial results for the first fiscal quarter ended April 3, 2015. Diluted earnings per share of $0.46, an increase of 4.5% over the prior year 20% growth in sales at Distribution to a record $311.5 million. Aerospace operating profit margin of 16.6%.
Signal Genetics, Inc. (NASDAQ:SGNL) has 3.40% insider ownership while its institutional ownership stands at 12.70%. In last trading activity company’s stock closed at $1.93. Signal Genetics, Inc. (NASDAQ:SGNL) on 30 April, announced that the College of American Pathologists has awarded accreditations to the firm’s Little Rock, Ark.-based laboratory.
On last trading day Embraer SA (NYSE:ERJ) fell -0.71% to close at $30.57. Its volatility for the week is 2.59% while volatility for the month is 2.15%. ERJ’s sales growth for past 5 years was 2.70% and its EPS growth for past 5 years was -6.70%. Embraer SA (NYSE:ERJ) monthly performance is -2.21%. Embraer SA (NYSE:ERJ) has said it hopes to devise a plan with Saab by June to export the Gripen from Brazil beginning in 2023.